Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith M Wilcoxen

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cell Chemical Biology|February 24, 2022
A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway diseaseLisa E J Douglas, James A Reihill, Melisa W Y Ho, et al.
Journal of Medicinal Chemistry|September 3, 2004
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonistsChen Chen, Keith M Wilcoxen, Charles Q Huang, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cell Chemical Biology|February 24, 2022
A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway diseaseLisa E J Douglas, James A Reihill, Melisa W Y Ho, et al.
Journal of Medicinal Chemistry|September 3, 2004
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonistsChen Chen, Keith M Wilcoxen, Charles Q Huang, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
Pageof 2